Loading, Please Wait...
PHILADELPHIA, July 31, 2018 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, will host a conference call on Tuesday, Aug. 7, 2018, at 8:30 a.m. ET to discuss corporate and financial results for the second quarter that ended June 30, 2018, and recent business highlights.
The call can be accessed by dialing (855) 851-4526 (domestic) or (720) 634-2901 (international), and entering passcode 5389949. To access a live audio webcast, please visit the “Investors” section of the Spark Therapeutics website at www.sparktx.com.
A replay of the call will be available for one week following the call and can be accessed by dialing (855) 859-2056 (domestic) or (404) 537-3406 (international), and entering passcode 5389949, or by visiting the “Investors” section of the Spark Therapeutics website at www.sparktx.com.
About Spark Therapeutics
At Spark Therapeutics, a fully integrated company committed to discovering, developing and delivering gene therapies, we challenge the inevitability of genetic diseases, including blindness, hemophilia and neurodegenerative diseases. We have successfully applied our technology in the first FDA-approved gene therapy in the U.S. for a genetic disease, and currently have three programs in clinical trials, including product candidates that have shown promising early results in patients with hemophilia. At Spark, we see the path to a world where no life is limited by genetic disease. For more information, visit www.sparktx.com, and follow us on Twitter and LinkedIn.
|Investor Contact:||Media Contact:|
|Ryan Asay||Monique da Silva|
|(215) 239-6424||(215) 282-7470|